-transparent.png){kind=logo}
A 1-beta-D-ribofuranosyl-5-fluorouracil-resistant clone, designated L5178Y/FUR, was established in this experiment. This is one of the colonies derived from a subculture which acquired resistance to 1-beta-D-ribofuranosyl-5-fluorouracil by passaging the L5178Y cells through four sucessive episodes of culture in Fischers' medium containing 1-beta-D-ribofuranosyl-5-fluorouracil; each analog treatment was followed by recovery intervals. In this subline, IC99 values for 1-beta-D-ribofuranosyl-5-fluorouracil was 0.57 muM, which was 24 times as great as in the parent line (0.0024 muM), and this subline showed a cross resistance to 5-fluorouracil. New alkylesters of 1-beta-D-ribofuranosyl-5-fluorouracil 5'-phosphate (FUMP-alkylesters) were synthesized and their antitumor activity was examined against 1-beta-D-5-fluorouracil-sensitive and -resistant L5178Y sublines. Only hexadecylester of 1-beta-D-ribofuranosyl-5-fluorouracil 5'-phosphate was effective, not only to 1-beta-D-ribofuranosyl-5-fluorouracil line but also to 1-beta-D-ribofuranolsyl-5-fluorouracil-resistant subline. Other compounds showed cross resistant in the 1-beta-D-ribofuranosyl-5-fluorouracil-resistant cells.
F Kanzawa, and
A Hoshi, and
K Kuretani
September 1980,
Journal of pharmacobio-dynamics,
F Kanzawa, and
A Hoshi, and
K Kuretani
October 1980,
Biochemistry,
F Kanzawa, and
A Hoshi, and
K Kuretani
January 1980,
Mutation research,
F Kanzawa, and
A Hoshi, and
K Kuretani
April 1988,
Cancer research,
F Kanzawa, and
A Hoshi, and
K Kuretani
October 1978,
Gan,
F Kanzawa, and
A Hoshi, and
K Kuretani
August 1983,
Journal of the National Cancer Institute,
F Kanzawa, and
A Hoshi, and
K Kuretani
January 1978,
Chemical & pharmaceutical bulletin,
F Kanzawa, and
A Hoshi, and
K Kuretani
January 2003,
Nucleosides, nucleotides & nucleic acids,
F Kanzawa, and
A Hoshi, and
K Kuretani
June 2018,
Biochemical and biophysical research communications,
F Kanzawa, and
A Hoshi, and
K Kuretani
August 1976,
The Journal of organic chemistry,
